Dr. Smith is leading a study to assess the safety and immunogenicity of one or two doses of Sing2016 M2SR H3N2 influenza vaccine delivered intranasally in a healthy pediatric population 6 months through 17 years of age. Further information about this study can be found at clinicaltrials.gov.
Dr. Woods is leading a multicenter, influenza challenge study in healthy adult volunteers to determine the optimal dose and safety of a recombinant H3N2 (A/Texas/71/2017 (H3N2, clade 3C3a) influenza strain. Further information about this study can be found at clinicaltrials.gov.
Dr. Woods and Dr. Walter are leading a registry study to enroll healthy persons for future participation in influenza, SARS-CoV-2, and other respiratory pathogen vaccination studies and influenza challenge studies.
Dr. Swamy and Dr. Dotters-Katz are leading a prospective observational study to evaluate the safety of COVID-19 vaccination in pregnant women. Further information about this study can be found at clinicaltrials.gov.
Dr. Walter and Dr. Schmader are leading a study to evaluate the safety of simultaneous versus sequential administration of mRNA COVID-19 vaccines and quadrivalent inactivated influenza vaccine (IIV4) in adults and adolescents. Further information about this study can be found at clinicaltrials.gov.
Dr. Schmader is leading a study to evaluate the safety of simultaneous vaccination with zoster vaccine recombinant (RZV) and quadrivalent adjuvanted inactivated influenza vaccine (aIIV4). Further information about this study can be found at clinicaltrials.gov.
Dr. Greenberg and Dr. Walter are leading a multicenter study to assess apnea following vaccination in premature infants receiving their standard of care two-month vaccinations. Further information about this study can be found at clinicaltrials.gov.
Dr. Walter is leading a phase 1/2/3 study to evaluate the safety, tolerability, and immunogenicity of an RNA vaccine candidate against COVID-19 in healthy children and young adults. Further information about this study can be found at clinicaltrials.gov.
Dr. Walter is leading a study to describe the safety, tolerability, immunogenicity and efficacy of RNA vaccine candidates against COVID-19 in healthy individuals. Further information about this study can be found at clinicaltrials.gov.
Dr. Walter is leading a study to evaluate the safety and efficacy of a booster dose of BNT162b2 against COVID-19 in participants ≥ 16 years of age. Further information about this study can be found at clinicaltrials.gov.
Dr. Walter is leading a Phase III Study of AZD1222 for the Prevention of COVID-19 in Adults. Further information about this study can be found at clinicaltrials.gov.
Dr. Vasudevan and Dr. Walter are leading a school-based intervention study to increase vaccine uptake among adolescents in the rural South. Further information about this study can be found at clinicaltrials.gov.
Dr. Walter and Dr. Naggie are leading an observational study to assess the prevalence and outcomes of primary pulmonary coccidioidomycosis (also referred to as Valley Fever (VF) Pneumonia or acute onset valley fever) in persons presenting with community acquired pneumonia. Recruitment will take place at sites in areas where VF is endemic, including Arizona and California. Further information about the trial can be found at clinicaltrials.gov.
Drs. Wilder and Walter are leading a study to evaluate the pharmacokinetics of Pretomanid in subjects with mild, moderate, and severe hepatic impairment to matched, non-hepatically impaired subjects. The primary study objectives are to evaluate the pharmacokinetics of a single oral dose of Pretomanid. More information about this trial can be found at clinicaltrials.gov.